We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Treatment of Adolescent Suicide Attempters (TASA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00080158
Recruitment Status : Completed
First Posted : March 26, 2004
Last Update Posted : November 4, 2013
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
New York State Psychiatric Institute

Brief Summary:
The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.

Condition or disease Intervention/treatment Phase
Depression Suicide, Attempted Drug: fluoxetine Drug: sertraline Drug: citalopram Drug: escitalopram Drug: bupropion Drug: mirtazapine Drug: venlafaxine Drug: lithium Behavioral: Cognitive Behavioral Therapy Phase 2 Phase 3

Detailed Description:

Suicide is the third leading cause of death in adolescents and is a major public health problem. Depression is the most common diagnosis for adolescent suicide attempts. Little is known about what treatment is best for these adolescents since they are usually excluded from participation in research studies.

Participants in this study will be randomly assigned to receive carefully monitored antidepressant medication with routine support and management, cognitive behavioral therapy (CBT), or a combination of antidepressant medication plus CBT.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : March 2004
Study Completion Date : June 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Suicide
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • At least one suicide attempt or interrupted attempt within the past 45 days
  • Continuously reside with a primary caretaker (parent, legal guardian, foster parent) for at least 6 months that can provide legal consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00080158

United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21287
United States, New York
New York University Child Study Center
New York, New York, United States, 10016
Columbia University at the New York State Psychiatric Institute
New York, New York, United States, 10032
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27705
United States, Pennsylvania
University of Pittsburgh - Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania, United States, 15213
United States, Texas
University of Texas, Southwestern Medical Center
Dallas, Texas, United States, 75235
Sponsors and Collaborators
New York State Psychiatric Institute
National Institute of Mental Health (NIMH)
Study Chair: Laurence Greenhill, MD

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: New York State Psychiatric Institute
ClinicalTrials.gov Identifier: NCT00080158     History of Changes
Obsolete Identifiers: NCT00183534
Other Study ID Numbers: #4623
U10MH066762 ( U.S. NIH Grant/Contract )
U10MH066775 ( U.S. NIH Grant/Contract )
U10MH066778 ( U.S. NIH Grant/Contract )
U10MH066769 ( U.S. NIH Grant/Contract )
U10MH066750 ( U.S. NIH Grant/Contract )
First Posted: March 26, 2004    Key Record Dates
Last Update Posted: November 4, 2013
Last Verified: July 2008

Keywords provided by New York State Psychiatric Institute:
Dysthymic Disorder

Additional relevant MeSH terms:
Suicide, Attempted
Self-Injurious Behavior
Behavioral Symptoms
Venlafaxine Hydrochloride
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Dopamine Agents
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Serotonin and Noradrenaline Reuptake Inhibitors
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Antidepressive Agents, Tricyclic